Cingulate Inc. (CING) income statement

CINGNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as CINGW

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30

$4.30−0.19 (-4.23%)

Close on Nov 13, 2026Market cap $62.53MP/E –Yield –

Cingulate Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Research & Development	9.77	9.45	15	9.00	8.41	5.09
General & Administrative	10	6.20	7.27	8.51	12	1.99
Operating Income	-20	-16	-23	-18	-21	-7.08
Interest Expense	0.90	0.03	0.79	0.29	0.03	0.05
Interest & Investment Income	0.37	0.16	–	–	–	–
Other Non-Operating Income	–	0.10	-0.78	-0.17	-0.03	-0.10
Asset Impairment Charges	–	–	–	0	0	0
Pretax Income	-22	-17	-24	-18	-21	-7.18
Net Income	-22	-17	-24	-18	-21	-7.18
EPS (Basic)(per share)	-4.44	-10.86	-311.99	-29.35	-52.08	–
EPS (Diluted)(per share)	-4.44	-10.86	-311.99	-29.35	-52.08	–
Shares Outstanding (Basic, Weighted)(shares)	5.06	1.52	0.08	0.60	0.40	–
Shares Outstanding (Diluted, Weighted)(shares)	5.06	1.52	0.08	0.60	0.40	–
Net Interest Income	-1.36	0.10	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Sep 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -450.6%

Financial strength

Current ratio: 3.90
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 357.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 3.01
Dividend yield: –

See a number that looks wrong?